Saranas, Inc, a medical device company, has announced that over 1,200 patients have been treated with the Early Bird Bleed Monitoring System, which was launched in 2019. It is the first and only FDA-approved bleed detection system that monitors and detects endovascular bleed complications through a novel application of bioimpedance sensors.
The system uses a fully functional introducer sheath, equipped with bioimpedance sensors, allowing bleeds to be detected and monitored in real time. For endovascular procedures where the femoral artery or vein are used to obtain vascular access, such as a transcatheter aortic valve replacement (TAVR) or mechanical circulatory support (MCS) device placement, this form of detection is novel.
With 1 in 5 patients expected to experience a bleed after a large-bore endovascular procedure, early intervention could reduce healthcare system costs and improve patient outcomes. Early Bird allows physicians to detect bleeding in real-time and take the necessary actions quickly to protect the outcomes of the procedure and aid recovery for the patient.
Saranas Interim CEO Kim Rodriguez said, “The new standard of care for bleed monitoring during endovascular procedures, not only helps to reduce intra- and post-procedural complications, but improve the patient experience. The adoption of the Early Bird system is a testimony to physicians embracing the benefits of early bleed detection for their patients and practice.”
